Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID06557512

A Pilot Trial of Adjuvant Hypofractionated Stereotactic Radiosurgery for Intermediate-risk Meningioma (SRS-AIM)

Led by University of California, San Francisco · Updated on 2026-05-18

23

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

Sponsors

U

University of California, San Francisco

Lead Sponsor

A

American Society of Clinical Oncology

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are evaluating the safety and effectiveness of hypofractionated stereotactic radiosurgery in patients who have had surgery for grade II meningiomas or recurrent grade I meningiomas. This study aims to assess this specialized radiation treatment, which uses focused high-energy rays to target tumor cells, after surgical removal of these brain tumors. It also explores survival rates, quality of life, financial impact, and gathers genetic information related to meningioma. The treatment involves a course of hypofractionated stereotactic radiosurgery delivered once daily over five consecutive days, each session lasting 15 to 30 minutes, provided there is no disease progression or unacceptable side effects. Participants also undergo regular imaging tests, including magnetic resonance imaging (MRI) throughout the study and computed tomography (CT) scans as needed. After completing the treatment, participants are followed up at 3 and 6 months, then annually for up to three years. During the study, participants will have their safety monitored by tracking any adverse events for up to one year. Researchers will also evaluate tumor control and survival outcomes over three years, along with assessing quality of life, financial burden, and treatment regrets using standardized questionnaires. Imaging tests help monitor disease status, and participants' overall health and function will be regularly assessed to understand the treatment's impact over time.

CONDITIONS

Brief Title

Adjuvant Hypofractionated Stereotactic Radiosurgery for Intermediate-risk Meningioma

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older at time of study entry
  • Ability to understand and willing to sign informed consent
  • Histologic diagnosis of newly diagnosed WHO grade 2 or recurrent WHO grade 1 meningioma with recent recurrence evidence
  • Gross-total surgical resection of meningioma within 180 days before enrollment
  • Pre-operative MRI available
  • ECOG performance status 0 or 1 (Karnofsky score 70 or higher)
  • Post-operative MRI anatomy suitable for hypofractionated radiosurgery as reviewed by investigators
Not Eligible

You will not qualify if you...

  • Concurrent participation in another interventional clinical study (except observational)
  • Extensive multifocal disease with 3 or more meningiomas or metastatic disease
  • Tumors located within 2mm of the optic apparatus or brainstem
  • Another active primary malignancy or recent malignancy unless in remission for 2 years without ongoing therapy
  • Pregnant female participants
  • Medical or psychiatric conditions interfering with safety or study evaluation
  • Uncontrolled seizures with more than 3 disabling seizures per day on medication
  • Previous intracranial radiotherapy overlapping the study treatment area

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - 5 days

Participants undergo hypofractionated stereotactic radiosurgery once daily on days 1 through 5, with each session lasting 15 to 30 minutes, unless disease progression or unacceptable toxicity occurs.

5 daily visits (in-person)

Follow-up

Duration - Up to 3 years

Participants are followed up with imaging and assessments to monitor health and treatment effects after completing radiosurgery.

Visits at 3 and 6 months, then at 1, 2, and 3 years

Trial Site Locations

Total: 1 location

1

University of California, San Francisco

San Francisco, California, United States, 94143

Actively Recruiting

Loading map...

Research Team

F

Francim Aguilar

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Similar Trials

177Lu-DOTATATE for Recurrent Meningioma: a Randomized Phase ...

Recurrent Meningioma

Actively Recruiting

12 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here